GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cansortium Inc (XCNQ:TIUM.U) » Definitions » Total Liabilities

Cansortium (XCNQ:TIUM.U) Total Liabilities : $178.9 Mil (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cansortium Total Liabilities?

Cansortium's Total Liabilities for the quarter that ended in Jun. 2024 was $178.9 Mil.

Cansortium's quarterly Total Liabilities increased from Dec. 2023 ($169.22 Mil) to Mar. 2024 ($174.60 Mil) and increased from Mar. 2024 ($174.60 Mil) to Jun. 2024 ($178.89 Mil).

Cansortium's annual Total Liabilities increased from Dec. 2021 ($119.89 Mil) to Dec. 2022 ($150.47 Mil) and increased from Dec. 2022 ($150.47 Mil) to Dec. 2023 ($169.22 Mil).


Cansortium Total Liabilities Historical Data

The historical data trend for Cansortium's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cansortium Total Liabilities Chart

Cansortium Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial 119.89 126.70 119.89 150.47 169.22

Cansortium Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 154.98 165.20 169.22 174.60 178.89

Cansortium Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cansortium's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=49.507+(98.431+3.882
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+17.398+0)
=169.2

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=177.803-8.585
=169.2

Cansortium's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=111.646+(43.433+3.447
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+20.365+0)
=178.9

Total Liabilities=Total Assets (Q: Jun. 2024 )-Total Equity (Q: Jun. 2024 )
=184.642-5.751
=178.9

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cansortium Total Liabilities Related Terms

Thank you for viewing the detailed overview of Cansortium's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Cansortium Business Description

Traded in Other Exchanges
Address
82 North East 26th Street, Suite 110, Miami, FL, USA, 33137
Cansortium Inc is licensed to produce and sell medical cannabis in Florida and Texas and is licensed to sell medical cannabis in Pennsylvania. Its medical cannabis products are offered in oral drops, capsules, topicals, syringes, dried flowers, pre-rolls, cartridges, and edibles. All of the company's products are marketed under the Fluent brand name. In Pennsylvania, the company's product portfolio is comprised of a variety of third-party branded medical cannabis products.

Cansortium Headlines

No Headlines